HomeInvestors HealthJNJ releases positive data on nipocalimab for myasthenia gravis in adolescents JNJ releases positive data on nipocalimab for myasthenia gravis in adolescents By investorshealth_a7mhmc October 15, 2024 FacebookTwitterPinterestWhatsApp JHVEPhoto/iStock Editorial via Getty Images Johnson & Johnson (NYSE:JNJ) said that a phase 2/3 trial of nipocalimab for myasthenia gravis met its primary endpoint in adolescents between 12 and 17 years old. Patients treated with nipocalimab plus standard of care saw a reduction in total Source link Previous articleStock Market News – Economic Fundamentals Are Weak – Inflation Ahead Given FED Rate CutNext articleWall Street Greed: Financial Crises Since 3500 BCE (CC) latest articles explore more 2 Reasons to Add Chipotle Stock to Your Radar Finance Pro Reacts to Investing Advice on TikTok (FUNNY) Tesla: Fairly Significant Doubt After The Cybercab Event Will China PUMP Your Crypto?! What Their Stimulus Means For Markets! Options Trading Crash Course: The #1 Beginner’s Guide to Make Money with Trading Options in 7 Days or Less! Bitcoin is one of the biggest bubbles in financial history: Niall Ferguson LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment.